Markt geschlossen· · GBp · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
Half-year ReportInterim Results for the period ended 30 June 2026LONDON, UK / ACCESS Newswire / September 28, 2026 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the"Company") (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2026.All financial amounts ar
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLICIntroductionLONDON, UK / ACCESS Newswire / September 3, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received notices to exercise warrant
Hemogenyx Pharmaceuticals Signs Definitive Collaboration Agreement with Cellin Technologies for Manufacturing and Commercialization of HG-CT-1 CAR-T Therapy in Estonia Binding Agreement Converts LOI into Execution of First Potential Near-Term Revenue ...
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.